BIOLIFE SOLUTIONS INC
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
BLFS$38.61+3.5%Stored close · as of Oct 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders’ Equity
| (In thousands, except share data) | Series APreferredStockShares | Series APreferredStockAmount | CommonStockShares | CommonStockAmount | AdditionalPaid-inCapital | AccumulatedOtherComprehensiveLoss | AccumulatedDeficit | TotalShareholders’Equity |
|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2022 | — | $— | 42,832,231 | $43 | $611,739 | $(679) | $(246,915) | $364,188 |
| Stock issued as consideration for SciSafe earnout | — | — | 116,973 | — | 2,263 | — | — | 2,263 |
| Fees incurred for registration filings | — | — | — | — | (132) | — | — | (132) |
| Stock-based compensation | — | — | — | — | 33,245 | — | — | 33,245 |
| Stock option exercises | — | — | 239,043 | — | 507 | — | — | 507 |
| Stock issued – on vested RSA units | 1,267,837 | 1 | (1) | — | — | — | ||
| Settlement of Global Cooling escrow | (216,024) | — | (5,115) | — | — | (5,115) | ||
| Common stock shares issued | — | — | 927,165 | 1 | 10,374 | — | — | 10,375 |
| Other comprehensive income | — | — | — | — | — | 334 | — | 334 |
| Net loss | — | — | — | — | — | — | (68,002) | (68,002) |
| Balance, December 31, 2023 | — | — | 45,167,225 | 45 | 652,880 | (345) | (314,917) | 337,663 |
| Stock-based compensation | — | — | — | — | 30,923 | — | — | 30,923 |
| Stock option exercises | — | — | 90,250 | — | 202 | — | — | 202 |
| Stock issued – on vested RSA units | — | — | 1,649,290 | 2 | (66) | — | — | (64) |
| Other comprehensive income | — | — | — | — | — | 369 | — | 369 |
| Net loss | — | — | (20,184) | (20,184) | ||||
| Balance, December 31, 2024 | — | — | 46,906,765 | 47 | 683,939 | 24 | (335,101) | 348,909 |
| Stock-based compensation | — | — | — | — | 22,993 | — | — | 22,993 |
| Stock option exercises | — | — | 10,000 | — | 18 | — | — | 18 |
| Stock issued – on vested RSA units | — | — | 1,068,803 | 1 | (1) | — | — | — |
| Common stock shares issued for PanTHERA Transaction | — | — | 213,360 | 4,455 | 4,455 | |||
| Other comprehensive income | — | — | — | — | — | 108 | — | 108 |
| Net loss | — | — | — | — | — | — | (4,595) | (4,595) |
| Balance, December 31, 2025 | — | $— | 48,198,928 | $48 | $711,404 | $132 | $(339,696) | $371,888 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.